Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02477878 · ClinicalTrials.gov registry record · Phase 1
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
A Phase 1 study of Multiple Myeloma and Lymphoma, sponsored by Bellicum Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 5
- Study locations
NCT02477878 is a Phase 1 study of Multiple Myeloma and Lymphoma that is active but no longer recruiting, run by Bellicum Pharmaceuticals. The registered enrollment target is 10 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT02477878, a Phase 1 study of Multiple Myeloma and Lymphoma, is active but no longer recruiting, sponsored by Bellicum Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 5
- Study locations
Study Summary
A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The treatment consists of increasing doses of BPX-501 T cell infusions to achieve a clinical response. Rimiducid will be investigated for the treatment of aGvHD after BPX-501 T cell infusion to determine a dose that can mitigate GvHD and preserve the graft versus leukemia effect.
Conditions Studied
Interventions
- DRUG Rimiducid
- BIOLOGICAL BPX-501
Study Locations (5)
Georgia
- BMT Program at Northside Hospital - Atlanta
Kansas
- University of Kansas - Westwood
New York
- Roswell Park - Buffalo
Oregon
- Oregon Health & Science University - Portland
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-07 |
| Est. Completion | 2033-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02477878
The ClinicalTrials.gov registry entry for NCT02477878 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is Bellicum Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Rimiducid is the first listed.
NCT02477878 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Georgia, Kansas, New York.
Frequently Asked Questions
What is clinical trial NCT02477878 about?
NCT02477878 is a clinical study titled "Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant". A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The treatment consists of increasing doses of BPX-501 T cell infusions to achieve a clinical response. Rimiducid will be investigated for the tre...
What is the current status of trial NCT02477878?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-07. Estimated completion is 2033-01.
What conditions does trial NCT02477878 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms.
What interventions are being tested in trial NCT02477878?
The interventions under investigation include: Rimiducid (DRUG), BPX-501 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02477878?
This trial is sponsored by Bellicum Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02477878 being conducted?
This trial has 5 study locations across Georgia, Kansas, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.